OraSure Technologies (OSUR) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic positioning and transformation

• Positioned for return to growth and margin expansion in 2025, supported by a reinvigorated innovation pipeline and a strengthened business foundation.

• Achieved significant operational turnaround, including right-sizing cost structure, automation, and process rigor, resulting in a Q3 cash balance of $279 million and no debt.

• Strategic transformation centers on cash rebuild, capability-building, and achieving core break-even, with disciplined execution and accountability.

• Focused on two core portfolios: effortless, instrument-free diagnostics and sample management solutions, targeting increased access and value in healthcare.

• Emphasis on expanding the product pipeline, diversifying the customer base, and leveraging strong commercial channels to drive profitable growth.

Diagnostics and innovation pipeline

• Diagnostics portfolio builds on leadership in infectious disease and STIs, with a strategy to expand test platforms, especially instrument-free and self-testing solutions.

• Sherlock Biosciences acquisition enhances molecular disposable OTC self-test capabilities, with the first CT&G test in clinical trials and FDA submission planned by year-end or 2025.

• Partnerships, such as with Sapphiros, provide access to digital lateral flow and innovative point-of-need platforms.

• Pipeline features molecular and "molecular-like" self-tests, with ongoing expansion into digital and next-gen platforms, including CRISPR-based tests.

• Near-term focus is on launching the CT&G test, with a broader roadmap for multiplex and power-free amplification technologies.

Sample management solutions and market expansion

• Sample management solutions, led by Oragene, are expanding to include new sample types like self-collected urine and blood, targeting non-invasive, FDA-cleared options.

• Colli-Pee, a self-collected urine device, is set for FDA submission by year-end or 2025, with studies showing strong patient preference.

• Partnership with Sapphiros enables access to self-collected blood products, broadening reach in genomics, clinical diagnostics, biotech, and pharma.

• Blood proteomics sample collection product launch planned for 2025, targeting a $0.7B market and leveraging protein biomarkers for disease detection.

• Diversified customer base reduces reliance on any single client, supporting resilience and growth.